Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Get in touch with Haiying
Contact Haiying, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck RackActions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Articles
Cost-effectiveness analysis of rezvilutamide versus bicalutamide in the treatment of metastatic hormone-sensitive prostate cancer
prostatic neoplasms health economics public health Data availability statement All data relevant to the study are included in the article or uploaded as online supplemental information.
Cost-effectiveness analysis of trastuzumab deruxtecan in patients with HER2-low advanced breast cancer based on DESTINY-Breast04
Mei Zhan1,2, Zijia Huang1,2, Ting Xu1,2, Xinyi Xu2, Hanrui Zheng1,2 and Fengbo Wu1,2* 1Department of Pharmacy, West China Hospital, Sichuan University, Chengdu, China 2West China School of Pharmacy, Sichuan University, Chengdu, China Background and purpose: Breast cancer is a rapidly raising healthcare problem worldwide.
Cost-effectiveness of PARP inhibitors in malignancies: A systematic review
PLOS ONE, Dec 2022 This is a preview of a remote PDF: https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0279286&type=printable Haiying Ding, Chaoneng He, Yinghui Tong, Qilu Fang, Xiufang Mi, Lingya Chen, Wenxiu Xin, Luo Fang. , PLOS ONE, 2022, Volume 17, Issue 12, DOI: 10.1371/journal.pone.0279286
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with Haiying
Contact Haiying, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack